Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29403, United States of America; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC 29403, United States of America.
Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, GA 30912, United States of America.
Exp Gerontol. 2020 Feb;130:110805. doi: 10.1016/j.exger.2019.110805. Epub 2019 Dec 5.
Osteoporosis is an age-related deterioration in bone health that is, at least in part, a stem cell disease. The different mechanisms and signaling pathways that change with age and contribute to the development of osteoporosis are being identified. One key upstream mechanism that appears to target a number of osteogenic pathways with age is kynurenine, a tryptophan metabolite and an endogenous Aryl hydrocarbon receptor (AhR) agonist. The AhR signaling pathway has been reported to promote aging phenotypes across species and in different tissues. We previously found that kynurenine accumulates with age in the plasma and various tissues including bone and induces bone loss and osteoporosis in mice. Bone marrow mesenchymal stem cells (BMSCs) are responsible for osteogenesis, adipogenesis, and overall bone regeneration. In the present study, we investigated the effect of kynurenine on BMSCs, with a focus on autophagy and senescence as two cellular processes that control BMSCs proliferation and differentiation capacity. We found that physiological levels of kynurenine (10 and 100 μM) disrupted autophagic flux as evidenced by the reduction of LC3B-II, and autophagolysosomal production, as well as a significant increase of p62 protein level. Additionally, kynurenine also induced a senescent phenotype in BMSCs as shown by the increased expression of several senescence markers including senescence associated β-galactosidase in BMSCs. Additionally, western blotting reveals that levels of p21, another marker of senescence, also increased in kynurenine-treated BMSCs, while senescent-associated aggregation of nuclear H3K9me3 also showed a significant increase in response to kynurenine treatment. To validate that these effects are in fact due to AhR signaling pathway, we utilized two known AhR antagonists: CH-223191, and 3',4'-dimethoxyflavone to try to block AhR signaling and rescue kynurenine /AhR mediated effects. Indeed, AhR inhibition restored kynurenine-suppressed autophagy levels as shown by levels of LC3B-II, p62 and autophagolysosomal formation demonstrating a rescuing of autophagic flux. Furthermore, inhibition of AhR signaling prevented the kynurenine-induced increase in senescence associated β-galactosidase and p21 levels, as well as blocking aggregation of nuclear H3K9me3. Taken together, our results suggest that kynurenine inhibits autophagy and induces senescence in BMSCs via AhR signaling, and that this may be a novel target to prevent or reduce age-associated bone loss and osteoporosis.
骨质疏松症是一种与年龄相关的骨骼健康恶化,至少在部分程度上是一种干细胞疾病。目前正在确定随着年龄的增长而改变并导致骨质疏松症发展的不同机制和信号通路。一种似乎针对许多成骨途径的关键上游机制是犬尿氨酸,一种色氨酸代谢物和内源性芳烃受体 (AhR) 激动剂。据报道,AhR 信号通路可促进跨物种和不同组织的衰老表型。我们之前发现犬尿氨酸在血浆和包括骨骼在内的各种组织中随年龄积累,并在小鼠中诱导骨丢失和骨质疏松症。骨髓间充质干细胞 (BMSC) 负责成骨、成脂和整体骨骼再生。在本研究中,我们研究了犬尿氨酸对 BMSC 的影响,重点关注自噬和衰老作为控制 BMSC 增殖和分化能力的两个细胞过程。我们发现,生理水平的犬尿氨酸 (10 和 100 μM) 破坏了自噬流,证据是 LC3B-II 的减少,以及自噬溶酶体的产生,以及 p62 蛋白水平的显著增加。此外,犬尿氨酸还诱导了 BMSC 中的衰老表型,如 BMSC 中几种衰老标志物的表达增加,包括衰老相关的β-半乳糖苷酶。此外,Western blot 显示,另一种衰老标志物 p21 的水平也在犬尿氨酸处理的 BMSC 中增加,而核 H3K9me3 的衰老相关聚集也显示出对犬尿氨酸处理的显著增加。为了验证这些影响实际上是由于 AhR 信号通路引起的,我们利用了两种已知的 AhR 拮抗剂:CH-223191 和 3',4'-二甲氧基黄酮,试图阻断 AhR 信号并挽救犬尿氨酸/AhR 介导的作用。事实上,AhR 抑制恢复了犬尿氨酸抑制的自噬水平,如 LC3B-II、p62 和自噬溶酶体形成所示,表明自噬流得到恢复。此外,AhR 信号的抑制阻止了犬尿氨酸诱导的衰老相关β-半乳糖苷酶和 p21 水平的增加,并阻止了核 H3K9me3 的聚集。总之,我们的结果表明,犬尿氨酸通过 AhR 信号抑制 BMSC 中的自噬并诱导衰老,这可能是预防或减少与年龄相关的骨丢失和骨质疏松症的新靶点。